Actinium Pharmaceuticals Inc (ATNM)

$9

-0.09

(-0.99%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Actinium Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 114.0K → 81.0K (in $), with an average decrease of 29.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -15.18M → -9.32M (in $), with an average increase of 28.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 48.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 253.0% return, outperforming this stock by 237.6%

Performance

  • $8.64
    $9.03
    $9.00
    downward going graph

    4.0%

    Downside

    Day's Volatility :4.32%

    Upside

    0.33%

    downward going graph
  • $4.00
    $9.86
    $9.00
    downward going graph

    55.56%

    Downside

    52 Weeks Volatility :59.43%

    Upside

    8.72%

    downward going graph

Returns

PeriodActinium Pharmaceuticals IncIndex (Russel 2000)
3 Months
68.54%
0.0%
6 Months
50.0%
0.0%
1 Year
-1.21%
-0.7%
3 Years
15.38%
-21.3%

Highlights

Market Capitalization
249.6M
Book Value
$1.59
Earnings Per Share (EPS)
-1.93
PEG Ratio
0.0
Wall Street Target Price
25.47
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.12%
Return On Equity TTM
-87.32%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
1.0M
EBITDA
-52.6M
Diluted Eps TTM
-1.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.73
EPS Estimate Next Year
0.04
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Actinium Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 183.0%

Current $9.00
Target $25.47

Technicals Summary

Sell

Neutral

Buy

Actinium Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc
43.54%
50.0%
-1.21%
15.38%
-37.11%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc
NA
NA
0.0
-1.73
-0.87
-0.32
NA
1.59
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc
Buy
$249.6M
-37.11%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Company Information

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o

Organization
Actinium Pharmaceuticals Inc
Employees
49
CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Industry
Health Technology

FAQs